zetomipzomib
zetomipzomib: developed by 1 company · 2 clinical trials tracked.
zetomipzomib evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could zetomipzomib → KZR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kezar Life Sciences, Inc. (KZR) Autoimmune Hepatitis; Lupus Nephritis | Phase 2 |
Clinical Trials (2)
A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg With Placebo in Patients With Active Lupus Nephritis
Primary endpoint: Proportion of Patients Achieving Complete Renal Response
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With Open-label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis
Primary endpoint: Patients Who Achieved Complete Biochemical Response
Frequently asked questions
Who is developing zetomipzomib?
zetomipzomib is being developed by Kezar Life Sciences, Inc..
How many clinical trials involve zetomipzomib?
BioSniper tracks 2 clinical trials involving zetomipzomib.